

1 **Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)**
2 **Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with**
3 **Nirmatrelvir-Ritonavir**

4

5 Eric Y. Dai¹, Kannon A. Lee¹, Audrey B. Nathanson¹, Ariana T. Leonelli¹, Brittany A.
6 Petros^{2,3,4,5}, Taylor Brock-Fisher⁵, Sabrina T. Dobbins⁵, Bronwyn L. MacInnis^{5,6}, Amelia
7 Capone⁷, Nancy Littlehale⁷, Julie Boucau⁸, Caitlin Marino⁸, Amy K. Barczak^{8,9,10}, Pardis C.
8 Sabeti^{5,6,11,12}, Michael Springer², Kathryn E. Stephenson^{1,8,10*}

9

10 ¹Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA,
11 USA

12 ²Department of Systems Biology, Harvard Medical School, Boston, MA, USA

13 ³Harvard-MIT MD/PhD Program, Boston, MA, USA

14 ⁴Harvard-MIT Program in Health Sciences and Technology, Cambridge, MA

15 ⁵Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA,
16 USA

17 ⁶Harvard T.H. Chan School of Public Health, Boston, MA, USA

18 ⁷Beth Israel Lahey Health Primary Care, Chelsea, MA, USA

19 ⁸Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of
20 Technology (MIT) and Harvard, Cambridge, MA, USA

21 ⁹Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA

22 ¹⁰Harvard Medical School, Boston, MA, USA

23 ¹¹Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, MA,

24 USA

25 ¹²Howard Hughes Medical Institute, Chevy Chase, MD, USA

26

27 *Corresponding Author: Kathryn E. Stephenson, MD, MPH, Center for Virology and Vaccine

28 Research, Beth Israel Deaconess Medical Center, E/CLS-1036, 300 Brookline Ave, Boston, MA

29 02215. Email: kstephen@bidmc.harvard.edu.

30

31 *Alternate Corresponding Author: Michael Springer, 200 Longwood Avenue, Systems Biology

32 Dept., Armenise Building 561, Boston, MA 02115. Email: Michael_springer@hms.harvard.edu.

33

34 **Keywords:** COVID-19, viral rebound, nirmatrelvir, Paxlovid, SARS-CoV-2

35

36 **Abstract:** 49 words

37

38 **Main text:** 1488 words

39

40 **ABSTRACT**

41
42 We measured viral kinetics of SARS-CoV-2 Omicron infection in 36 mRNA-vaccinated
43 individuals, 11 of whom were treated with nirmatrelvir-ritonavir (NMV-r). We found that NMV-
44 r was associated with greater incidence of viral rebound compared to no treatment. For those that
45 did not rebound, NMV-r significantly reduced time to PCR conversion.

46
47 **BACKGROUND**

48
49 The protease inhibitor nirmatrelvir-ritonavir (NMV-r) decreases the risk of severe COVID-19
50 (coronavirus disease 2019) in unvaccinated high-risk outpatients with SARS-CoV-2 (severe
51 acute respiratory syndrome coronavirus 2) infection^{1,2}, but has not shown clinical benefit in low-
52 risk and/or vaccinated individuals³. NMV-r accelerates time to viral suppression in a range of
53 populations^{1,3,4}, suggesting that there may be a public health benefit of NMV-r treatment if
54 reduced viral shedding translated to decreased transmission. However, there are concerns that
55 cases of viral rebound following NMV-r cessation with prolonged viral shedding would negate
56 any such public health benefit. Such cases have been described in mRNA-vaccinated individuals
57 infected with the Omicron variant, where viral rebound was characterized by recurrence of
58 symptoms, high viral load, a long duration to re-suppression of virus, and the presence of
59 culturable virus, though not severe disease or impaired SARS-CoV-2 specific immune
60 responses⁵⁻⁸.

61 The data on the incidence of viral rebound in treated and untreated populations is mixed,
62 primarily due to varying definitions of rebound, methods of ascertaining events, and patient

63 populations^{1,4,9-11}. In the largest dataset of viral kinetics in untreated mRNA-vaccinated
64 individuals infected with the Omicron variant, viral rebound (defined with PCR monitoring)
65 occurred in 6% of 494 infections¹⁰. To date, however, there is no direct comparison of the
66 incidence of viral rebound in NMV-r-treated and untreated individuals in a similar mRNA-
67 vaccinated population.

68 To address this knowledge gap, we conducted a prospective observational study of 36
69 individuals newly diagnosed with SARS-CoV-2 infection in Massachusetts, United States
70 between March and May 2022, 11 of whom had initiated therapy with NMV-r at the time of
71 enrollment. We collected anterior nares samples daily for at least 14 days for viral load
72 quantification and whole genome viral sequencing; 1 additional swab was collected at enrollment
73 for viral culture. All participants completed questionnaires reporting demographics, past medical
74 history, COVID-19 vaccination status, and symptoms.

75

76 **METHODS**

77

78 **Study Participants**

79 Individuals were eligible for participation if greater than 2 years old and diagnosed with SARS-
80 CoV-2 infection by rapid antigen test or polymerase chain reaction (PCR) within 7 days of
81 enrollment. The protocol was approved by the Beth Israel Deaconess Medical Center
82 institutional review board. Study staff reviewed study requirements verbally with eligible
83 individuals and obtained and documented verbal consent, and verbal assent for children as
84 applicable.

85

86 **Endpoint Assessments**

87 Detailed methods with citations are described in the supplement. Participants self-collected
88 (unsupervised) anterior nasal swab specimens at home for a minimum of 14 days. Virus was
89 quantified with the Quaeris SARS-CoV-2 Assay, a real-time reverse transcription polymerase
90 chain reaction (rRT-PCR) test. Cycle threshold (Ct) values <35 were considered positive. Viral
91 rebound was defined as at least 2 negative (Ct \geq 35) PCR results followed by at least 2 positive
92 (Ct<35) results. SARS-CoV-2 genomes were sequenced and aligned to the Wuhan-Hu-1
93 reference genome. Single-nucleotide variations (SNV) were called relative to Wuhan-Hu-1 and
94 visualized relative to the BA.2 reference, as all 8 sequenced samples were of the BA.2 lineage
95 and its descendants. Viral culture was performed from an enrollment swab and assessed semi-
96 quantitatively by median tissue culture infectious dose assay (TCID₅₀).

97

98 **RESULTS**

99

100 36 participants were enrolled between March 4, 2022 and May 25, 2022. The median age was 44
101 years (range 25-48) in the NMV-r group, and 16 years (range 5-66) in the untreated group
102 (Supplemental Table 1). Participants in the NMV-r group were more likely than in the untreated
103 group to have comorbidities, to have ever smoked/vaped, and to be overweight/obese. There was
104 a median of 3 prior COVID-19 vaccine doses in both groups; all participants had received at
105 least one mRNA vaccine. All sequenced viruses were BA.2 or a sub-lineage.

106 One (1) out of 25 individuals in the untreated group (4%) had virologic rebound
107 compared to 3 out of 11 (27%) in the NMV-r group (p=.04, Chi-square test, Figure 1A-B).
108 Among individuals who did not have viral rebound, the duration of PCR positivity from initial

109 positive test (diagnosis) to last positive PCR was significantly shorter in the NMV-r group vs. the
110 untreated group (median 3.5 vs. 7 days, $p=.0006$ by Mann-Whitney test, Figure 1C). This
111 difference in time from initial diagnosis to last positive PCR was no longer significant when
112 including rebound cases where last positive test was counted at end of rebound (Supplemental
113 Table 4). Among those with viral rebound following NMV-r, the median time to rebound from
114 end of initial infection (first negative test) was 5 days (range 2-7) and the median peak virus
115 level during rebound was Ct=19 (range 24.8 to 17.2). In the single case of rebound without
116 treatment, time to rebound was 5 days and peak virus level was Ct=30.3. There was no
117 difference in peak detected virus level during the initial infection period between those treated
118 with NMV-r who had virologic rebound, and those that did not (median Ct=29 vs. Ct=27.5,
119 Figure 1D), though there was a suggestion of a longer time to undetectable viral load (Ct \geq 40)
120 (median 5 vs. 3 days, Figure 1E). Within the NMV-r group, live virus was cultured from 1/3
121 samples (collected at enrollment) among rebounders compared to 0/4 samples from non-
122 rebounders (Figure 1F). Baseline symptoms and other characteristics were similar between
123 rebounders and non-rebounders in the NMV-r group (except that the only immunocompromised
124 individual in cohort was in the rebound group, Supplemental Table 2). All NMV-r treated
125 participants had received at least 3 mRNA vaccinations. One case of NMV-associated rebound
126 was asymptomatic.

127 Viral isolates from initial and rebound infections were sequenced from 4 non-rebounders
128 and 3 rebounders (both pre- and post-rebound) in the NMV-r group. One single nucleotide
129 variation (C25416T) was detected in viruses from initial infection that was unique to non-
130 rebounders compared to rebounders, who all possessed the ancestral allele both before and
131 following NMV-r treatment (Figure 1G; pre-rebound samples with poorer sequence quality

132 included in Supplemental Figure 1), Of note, 2 rebounders were from the same household and
133 thus epidemiologically and genomically linked. This nucleotide variation (C25416T) was present
134 on the accessory gene ORF3a. No mutations associated with NMV-r resistance were identified in
135 initial or rebound viruses.

136

137 **DISCUSSION**

138

139 In this small prospective observational study of mRNA-vaccinated individuals, we found that
140 viral rebound was observed significantly more often following NMV-r treatment compared to no
141 treatment. In the 3 cases of rebound following NMV-r, viral kinetics during the period of
142 rebound were similar to that observed in acute infection, with an abrupt rise to high peak levels
143 (median Ct=19) and 6-12 days to viral clearance. In the rebound case following no treatment,
144 viral kinetics were more akin to a so-called “blip”, e.g., 2 days of positive values with peak
145 Ct=30.3.

146 The baseline incidence of rebound in the untreated group was 4% when rebound was
147 defined as at least 2 negative (Ct \geq 35) PCR results followed by at least 2 positive (Ct<35) results.
148 Estimates of the incidence of rebound vary widely across the literature because of differences in
149 methodology^{4,9-11}. Our result is consistent with the 6% rate reported in a prospective
150 observational cohort of mRNA-vaccinated individuals infected with Omicron, where viral
151 rebound was defined using similar PCR criteria. Among the 11 individuals who were treated
152 with NMV-r in our study, we observed viral rebound in 3 cases (27%). Given the small number
153 of events, a precise estimate of the true incidence of NMV-r viral rebound in mRNA-vaccinated
154 individuals cannot be made from this data.

155 For those that did not have viral rebound, NMV-r treatment significantly reduced the
156 duration of infection (median 7 vs. 3.5 days). However, when including rebounders in the
157 analysis, the difference in time from diagnosis to last negative PCR (including rebound period)
158 was no longer significant. Further studies with larger sample sizes and/or in dense transmission
159 units (e.g., households) are required to determine if treating low-risk/vaccinated populations with
160 NMV-r can prevent secondary SARS-CoV-2 transmission.

161 It is unclear why rebound occurs in some individuals following NMV-r treatment and not
162 in others. Our data suggests that there may be differences in the early dynamics of infection that
163 are unmasked by treatment. In comparison to non-rebounders, infection in rebounders took
164 longer to suppress to undetectable ($C_t \geq 40$) with NMV-r (median 5 vs. 3 days) and viruses from
165 initial infection were more likely to grow in live culture (1/3 vs. 0/4 cultures). Further, we found
166 that sequenced viruses in the rebound group lacked a single nucleotide variation in Orf3a, an
167 accessory gene that is not associated with NMV-r resistance but when deleted, significantly
168 attenuates replicative capacity in animal models¹². However, given that viruses from 2 of the
169 NMV-r rebounders are epidemiologically linked, the lack of this mutation may not be
170 meaningful.

171 NMV-r remains a critical tool for treating outpatient SARS-CoV-2 infection in patients
172 who are at high risk for progressing to severe disease, e.g., individuals with comorbidities who
173 are unvaccinated or may have diminished vaccine-induced immunity. Optimal deployment of
174 NMV-r as an antiviral agent will require defining the effect in other populations, identifying the
175 host and viral factors that put treated individuals at risk for rebound, and determining the
176 consequences of rebound on forward transmission.

177

178 **ACKNOWLEDGEMENTS**

179

180 We thank the participants and staff at the Center for Virology and Vaccine Research Clinical
181 Trials Unit, the Harvard Catalyst Clinical Research Center, and the Beth Israel Deaconess
182 Primary Care—Chelsea Clinic.

183

184 **FUNDING SOURCES**

185

186 This study was supported by the Massachusetts Consortium for Pathogen Readiness (K.E.S. and
187 A.K.B.), Beth Israel Deaconess Medical Center (K.E.S.), National Institutes of Health (R01-
188 GM120122 to M.S.), Harvard Catalyst, the National Institute of General Medical Sciences
189 (T32GM007753 to B.A.P.), the Centers for Disease Control and Prevention (CDC) COVID-19
190 baseline genomic surveillance contract to the Clinical Research Sequencing Platform
191 (75D30121C10501 to B.L.M.), a CDC Broad Agency Announcement (75D30120C09605 to
192 B.L.M.), the National Institute of Allergy and Infectious Diseases (U19AI110818 and
193 U01AI151812 to P.C.S.), and Howard Hughes Medical Institute (P.C.S.). The BSL3 laboratory
194 where viral culture work was performed is supported by the Harvard Center for AIDS Research
195 (CFAR) (US National Institutes of Health P30 AI060354).

196

197

198 **CONFLICT OF INTERESTS**

199

200 P.C.S. is a co-founder of, shareholder in, and scientific advisor to Sherlock Biosciences, Inc; she
201 is also a Board member of and shareholder in Danaher Corporation. P.C.S. has filed IP related to
202 genome sequencing and analysis. The authors declare no other conflicts of interests.

203 **FIGURE LEGEND**

204

205 **Figure 1. Viral kinetics of SARS-CoV-2 infection in participants treated and not treated**

206 **with NMV-r.** (A-B) The magnitude of virus is plotted on the y axis as Cycle threshold (Ct)

207 value; numbers are plotted inversely to show that a lower Ct value signifies a higher amount of

208 virus. Days following diagnosis (first positive test) are plotted on the x axis. Grey shading

209 indicates the Ct threshold (35) for negative/positive determination. Left panels depict non-

210 rebounders. Right panels depict rebounders. Participants who did not receive treatment (N=25)

211 are plotted in (A). Participants who received NMV-r treatment are plotted in (B). Dotted line

212 indicates Ct=35, the threshold for positivity. ND=not detected, plotted as Ct=40. (C) Duration of

213 viral shedding (time to negative PCR up to at least 14 days) for no treatment and NMV-r

214 treatment groups. Open circles indicate rebounders. (D) Peak virus level (lowest Ct) detected

215 during initial infection period in NMV-r treatment group plotted by rebound status. (E) Time to

216 suppression (days to negative PCR, Ct<40) following initiation of NMV-r plotted by rebound

217 status. (F) SARS-CoV-2 live virus culture titer (TCID₅₀) of nasal samples from day of

218 enrollment in NMV-r treatment group plotted by rebound status. ND=not detected. Solid red bars

219 in (C-F) indicate median values. (G) Plot of SARS-CoV-2 whole genome alignment, relative to

220 the BA.2 reference sequence, for viruses in NMV-r treatment group plotted by rebound status

221 (“no rebound”, “pre-rebound”, and “post-rebound”). Single nucleotide variations from reference

222 sequence are noted in color. Participant numbering for sequence analysis (e.g. “Rebound

223 Participant #1” etc.) is arbitrary for publication purposes and does not match study identification

224 numbers or the lettering system used in Supplemental Table 2.


225

REFERENCES

1. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. *N Engl J Med* 2022;386:1397-408.
2. Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of paxlovid in reducing severe COVID-19 and mortality in high risk patients. *Clin Infect Dis* 2022.
3. Press release: Pfizer announced additional Phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death 2021. URL: <https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results#.YuqqMD0XAEc.link>. Accessed 03 August 2022.
4. Li H, Gao M, You H, et al. Association of nirmatrelvir/ritonavir treatment on upper respiratory SARS-CoV-2 RT-PCR negative conversion rates among high-risk patients with COVID-19. *Clin Infect Dis* 2022.
5. Epling BP, Rocco JM, Boswell KL, et al. COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir. medRxiv [Preprint, posted 17 June 2022] doi: 10.1101/2022.06.16.22276392.
6. Charness M, Gupta K, Stack G, et al. Rapid relapse of symptomatic omicron SARS-CoV-2 infection following early suppression with nirmatrelvir/ritonavir. ResearchSquare [Preprint, posted 23 May 2022]. doi.org/10.21203/rs.3.rs-1588371/v3.
7. Boucau J, Uddin R, Marino C, et al. Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for COVID-19. *Clin Infect Dis* 2022.

8. Malden DE, Hong V, Lewin BJ, et al. Hospitalization and emergency department encounters for COVID-19 after paxlovid treatment - California, December 2021-May 2022. *MMWR Morb Mortal Wkly Rep* 2022;71:830-3.
9. Ranganath N, O'Horo JC, Challener DW, et al. Rebound phenomenon after nirmatrelvir/ritonavir treatment of coronavirus disease-2019 in high-risk persons. *Clin Infect Dis* 2022.
10. Hay JA, Kissler SM, Fauver JR, et al. The impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound. *medRxiv* [Preprint, posted 22 June 2022] doi.org/10.1101/2022.01.13.22269257.
11. Deo R, Choudhary MC, Moser C, et al. Viral and symptom rebound in untreated COVID-19 infection. *medRxiv* [Preprint, posted 02 August 2022] doi.org/10.1101/2022.08.01.22278278.
12. Liu Y, Zhang X, Liu J, et al. A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions. *Nat Commun* 2022;13:4337.

FIGURE 1



SUPPLEMENTAL INFORMATION

Viral Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Omicron Infection in mRNA-Vaccinated Individuals Treated and Not Treated with Nirmatrelvir-Ritonavir

Table of Contents

Supplemental Methods.....	2
Supplemental Tables.....	5
Supplemental Table 1. Baseline Characteristics	5
Supplemental Table 2. Detailed description of participants in NMV-r treatment group by rebound status	6
Supplemental Table 3. Virologic characteristics of SARS-CoV-2 infection by group	8
Supplemental Table 4. Duration of PCR positivity in no treatment group vs. NMV-r treatment group	9
Supplemental Figures.....	10
References.....	11

Supplemental Methods

Viral Load Quantification

Viral load quantification was measured with the Quaeris SARS-CoV-2 Assay, a real-time reverse transcription polymerase chain reaction (rRT-PCR) test using the Luna Probe One-Step RT-qPCR Kit (No ROX) [NEB E3007]¹. The SARS-CoV-2 primer and probe set is designed to detect RNA from the SARS-CoV-2 N1 and RdRP genes and the human RNase P gene in nasal specimens from suspected patients. The Quaeris assay employs a RNaseP internal control to determine that the self-collection resulted in a sample of appropriate quality and quantity of RNA. When received by the laboratory, samples are first rehydrated with 300 µl phosphate buffered saline (PBS), then inactivated at 65°C and subsequently used directly as input for the Quaeris assay. There is no extraction step. rRT-PCR is performed on an Applied Biosystem Quantstudio 7 instrument (software version 1.7). Liquid handling is automated using either the Tecan Fluent 1080, or the Hamilton Star, or the Multidrop combi dispenser. Cycle threshold is reported for N1 gene.

SARS-CoV-2 Whole Genome Sequencing

Sequencing of viral isolates from initial and rebound infections was attempted for 8 unique participants in the NMV-r group (5 non-rebounders, and 3 rebounders, pre- and post-rebound). Viral RNA was extracted from anterior nares swabs using the KingFisher Flex System with the MagMAX MirVana Total RNA Isolation Kit. Illumina sequencing libraries were constructed using the ARTIC v4.1 multiplexed primer set as previously described² and sequenced on an Illumina NextSeq instrument. The viral-ngs pipeline (<https://github.com/broadinstitute/viral-pipelines>) was used to demultiplex reads, remove adaptor and contaminant sequences, deplete

human reads, and assemble genomes to the reference sequence NC_045512.2. Complete genomes (> 24000 unambiguous bp in assembled genome length) were assigned Pango lineages using Nextclade³ (<https://clades.nextstrain.org>). Visualization was prepared using snipit (<https://github.com/aineniameh/snipit>) to label single nucleotide variants relative to the BA.2 reference sequence (GISAID ID: EPI_ISL_8128463). Notably, the pre-rebound samples for Rebound Participants #2 and #3 were of poorer quality (3053 and 20261 unambiguous bases, respectively), but were included to demonstrate the presence of the ancestral allele before, and thus not in response to selective pressures from, drug treatment in all cases where the base was unambiguously resolved. Participant numbering for sequence analysis (e.g. “Rebound Participant #1” etc.) is arbitrary for publication purposes and does not match study identification numbers or the lettering system used in Supplemental Table 2.

SARS-CoV-2 Culture

We performed viral culture in the BSL3 laboratory of the Ragon Institute of Massachusetts General Hospital (MGH), Massachusetts Institute of Technology (MIT), and Harvard. Viral culture was assessed semi-quantitatively by median tissue culture infectious dose assay (TCID₅₀) as previously reported⁴. In brief, viral swabs for culture were placed in viral transport media for storage and transport. Viral transport media was filtered through a 0.65µm filter; then used to inoculate Vero-E6 cells in serial dilutions in a 96-well format. Wells were observed with a light microscope on day 7 post-infection, and wells demonstrating CPE were scored as positive.

Statistical Analysis

Viral rebound was defined as at least 2 negative ($Ct \geq 35$) PCR results followed by at least 2 positive ($Ct < 35$) results. These criteria were chosen to enhance comparability with data in Li et al.⁵ and Hay et al.⁶. The incidence of viral rebound was compared between treated and untreated participants using Chi-square test. Duration of infection was calculated as days from initial positive test (diagnosis) to last positive PCR ($Ct < 35$). Since follow up was variable beyond 14 days, positive values after 14 days was calculated as 14 days. Median duration of infection was compared between treated and untreated participants using Mann-Whitney test, both with and without rebound cases.

Supplemental Tables

Supplemental Table 1. Baseline Characteristics

	No Treatment (N=25)	NMV-r (N=11)
Age (Years)		
Median [Min, Max]	16 [5, 66]	44 [25, 48]
Sex at Birth		
Male	11 (44%)	4 (36%)
Female	14 (56%)	7 (64%)
Gender Identity		
Male	11 (44%)	4 (36%)
Female	13 (52%)	6 (55%)
Nonbinary	1 (4%)	1 (9%)
Race		
White	25 (100%)	11 (100%)
Asian	0 (0%)	0 (0%)
Black or African American	0 (0%)	0 (0%)
Native Hawaiian or Other Pacific Islander	0 (0%)	0 (0%)
Multiple/Other	0 (0%)	0 (0%)
Ethnicity		
Hispanic or Latino/Latinx	2 (8%)	0 (0%)
Not Hispanic or Latino/Latinx	23 (92%)	11 (100%)
Comorbidities		
None	14 (56%)	9 (36%)
Pulmonary	3 (12%)	4 (36%)
Immunocompromised	0 (0%)	1 (9%)
Cardiac	0 (0%)	1 (9%)
Other	0 (0%)	6 (55%)
Other Risk Factors		
Ever Smoker / Vape User	2 (8%)	2 (18%)
Overweight, Not Obese	6 (24%)	5 (45%)
Obese	2 (8%)	2 (18%)
COVID-19 Vaccines (# Received)		
Median [Min, Max]	3 [2, 4]	3 [2, 4]

Supplemental Table 2. Detailed description of participants in NMV-r treatment group by rebound status

No Rebound (N=8)								
	Age Range	Sex at Birth	Risk Factors	Prior Infection	COVID-19 Vaccines	Days from Vaccination	Acute Symptoms [Max Duration]	Rebound Symptoms
A*	21-25	Female	Diabetes	No	Pfizer x 3	164	Cough, sore throat, fatigue [3 days]	NA
B	46-50	Male	Former/Current Smoker BMI>30	No	Pfizer x 3	151	Cough, sore throat, fever (99) [6 days]	NA
C	31-35	Female	Asthma BMI>25	No	Pfizer x 3	177	Runny nose, decreased taste, sneezing, abdominal pain, joint pain, fatigue, cough, sore throat, chills, fever (101.5), headache, dizziness, muscle aches, diarrhea [8 days]	NA
D	46-50	Male	Asthma BMI>25	No	Moderna x 2 Pfizer x 1	162	Runny nose, sneezing, fatigue, cough, shortness of breath, chills, fever (not measured), muscle aches [3 days]	NA
E	26-30	Male	None	No	Pfizer x 3	161	Fatigue, cough, sore throat, chills, fever (99), chest pain, headache [4 days]	
F	46-50	Female	Former/Current Smoker	No	Pfizer x 2 Moderna x 1	182	Ear pain, stuffy nose, sneezing, no appetite, abdominal pain, joint pain, fatigue, cough, shortness of breath, sore throat, chills, fever (100.9), chest pain, dizziness, muscle aches, diarrhea [3 days]	NA
G	46-50	Female	Asthma Hypertension BMI>30	No	Pfizer x 2 Moderna x 1	196	Ear pain, runny nose, sneezing, no appetite, abdominal pain, fatigue, cough, shortness of breath, sore throat, chills, fever (not measured), chest pain, headache, muscle aches, diarrhea [5 days]	NA
H	36-40	Female	BMI>25	No	J&J x 1 Moderna x 1	184	Runny nose, sneezing, fatigue, cough, sore throat, chills, fever (101.7), headache, muscle aches [4 days]	NA
							Median 4 days symptoms (Range 3-8 days)	

Supplemental Table 2. Continued.

Rebound (N=3)								
	Age Range	Sex at Birth	Comorbidities	Prior Infection	COVID-19 Vaccines	Days from Vaccination	Acute Symptoms [Max Duration]	Rebound Symptoms
I	41-45	Female	Chronic skin condition** BMI>25	No	Moderna x 2 Pfizer x 1	189	Runny nose, fatigue, sore throat, fever (100.2), headache [3 days]	Asymptomatic
J	41-45	Female	Autoimmune condition on natalizumab** BMI>25	No	Pfizer x 4	68	Runny nose, sneezing, fatigue, sore throat, dizziness [7 days]	Runny nose, sneezing, fatigue, sore throat, muscle aches [3 days]
K	46-50	Male	Asthma Diverticulosis	No	Pfizer x 3	155	Joint pain, fatigue, cough, sore throat, dizziness, muscle aches, diarrhea [5 days]	Fatigue, myalgia, runny nose [3-5 days]
							Median 5 days symptoms (Range 3-7 days)	

*Note: identifiers A-K are changed from participant study ID and are used for publication only. They are arbitrary and do not correspond to the numbering system used for sequence data presented in Figure 1 and Supplemental Figure 1; this numbering system is also arbitrary.

**Specific condition not described to avoid identification.


Supplemental Table 3. Virologic characteristics of SARS-CoV-2 infection by group

	No Treatment			NMV-r Treatment		
	No Rebound	Rebound	Overall	No Rebound	Rebound	Overall
Number	24	1	25	8	3	11
Time from first positive test (diagnosis) to last positive PCR (Ct<35) – Median Days [Min, Max]						
Including rebound, not capped at 14 days	7 [2, 15]	15 [NA]	7 [2, 15]	3.5 [1, 7]	20 [14, 21]	4 [1, 21]
Including rebound, capped at 14 days	7 [2, 14]	14 [NA]	7 [2, 14]	3.5 [1, 7]	14 [14, 14]	4 [1, 14]
Initial infection only, capped at 14 days	7 [2, 14]	8 [NA]	7 [2, 14]	3.5 [1, 7]	4 [3, 6]	4 [1, 7]
Peak viral level (lowest Ct) – Median Ct [Min, Max]						
Week 1, from first positive test (diagnosis)	24.1 [35, 15.9]	17.5 [NA]	23.3 [35, 15.9]	27.5 [40, 18.2]	29 [32.3, 22]	27.7 [40, 18.2]
Week 2, from first positive test (diagnosis)	35.0 [40, 25.8]	29.8 [NA]	34.5 [40, 25.8]	40 [40, 35.9]	19 [24.8, 17.2]	40 [40, 17.2]
During rebound infection	-	30.3 [NA]	-	-	17.2 [24.8, 19]	-
Time from first NMV-r dose to last positive PCR – Median Days [Min, Max]						
Initial infection only, Ct<35=positive	-	-	-	3 [2, 5]	3 [3, 5]	3 [2, 5]
Initial infection, only, Ct<40=positive	-	-	-	3 [2, 6]	5 [3, 5]	3 [2, 5]
Time from first symptom to last positive PCR (Ct<35) – Median Days [Min, Max]						
Initial infection only	-	-	-	4 [2, 7]	5 [3, 8]	4 [2, 8]
Days of negative PCRs before first positive PCR of rebound (Ct<35=positive) – Median Days [Min, Max]						
	-	5 [NA]	-	-	5 [2, 7]	-
Time from first positive test (diagnosis) to rebound (Ct<35) – Median Days [Min, Max]						
	-	14 [NA]	-	-	9 [9, 12]	-
Time from first positive test during rebound to last positive PCR (Ct<35) – Median Days [Min, Max]						
	-	2 [NA]	-	-	10 [6, 12]	-
Days to peak viral level (lowest Ct) during rebound – Median Days [Min, Max]						
	-	2 [NA]	-	-	2 [2, 3]	-

Supplemental Table 4. Duration of PCR positivity in no treatment group vs. NMV-r treatment group

Time from first positive test (diagnosis) to last positive PCR, including rebound. Follow up capped at 14 days.	Mann-Whitney test
No treatment vs. NMV-r	P=0.1462
No treatment vs. NMV-r, excluding rebounders	P=0.0006

Supplemental Figures



Supplemental Figure 1. SARS-CoV-2 whole genome sequences, expanded to include all pre-rebound samples. Plot of SARS-CoV-2 whole genome alignment, relative to the BA.2 reference sequence, for viruses in NMV-r treatment group plotted by rebound status (“no rebound”, “pre-rebound”, and “post-rebound”). Single nucleotide variations from reference sequence are noted in color. Pre-rebound samples for Rebound Participants #2 and #3 were of poorer quality (3053 and 20261 unambiguous bases, respectively), but were included to demonstrate the presence of the ancestral allele before, and thus not in response to selective pressures from, drug treatment in all cases where the base was unambiguously resolved. Participant numbering for sequence analysis (e.g. “Rebound Participant #1” etc.) is arbitrary for publication purposes and does not match study identification numbers or the lettering system used in Supplemental Table 2.

References

1. Emergency Use Authorization (EUA) Summary Quaceris SARS-CoV-2 Assay. Available at: <https://www.fda.gov/media/149445/download> 2021.
2. Siddh KJ, Krasilnikova LA, Moreno GK, et al. Transmission from vaccinated individuals in a large SARS-CoV-2 Delta variant outbreak. *Cell* 2022;185:485-92 e10.
3. Aksamentov I, Roemer C, Hodcroft EB, et al. Nextclade: clade assignment, mutation calling and quality control for viral genomes. *Journal of Open Source Software* 2021;6(67), 3773..
4. Yonker LM, Boucau J, Regan J, et al. Virologic features of severe acute respiratory syndrome coronavirus 2 infection in children. *J Infect Dis* 2021;224:1821-9.
5. Li H, Gao M, You H, et al. Association of nirmatrelvir/ritonavir treatment on upper respiratory SARS-CoV-2 RT-PCR negative conversion rates among high-risk patients with COVID-19. *Clin Infect Dis* 2022.
6. Hay JA, Kissler SM, Fauver JR, et al. The impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound. medRxiv [Preprint, posted 22 June 2022] doi.org/10.1101/2022.01.13.22269257.